Nargenicin A1

Nargenicin A1 is an antibiotic agent against various Gram-positive bacteria. Nargenicin A1 shows anti-inflammatory activity. Nargenicin A1 protects HINAE cells against Tacrolimus (HY-13756) -induced DNA damage and apoptosis. Nargenicin A1 can also be used for the research of acute myeloid leukemia[1].

Product Specifications

CAS Number

[70695-02-2]

UNSPSC

12352005

Target

Antibiotic; Apoptosis; Bacterial; NF-κB

Type

Reference compound

Related Pathways

Anti-infection; Apoptosis; NF-κB

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Infection; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/nargenicin-a1.html

Solubility

10 mM in DMSO

Smiles

C/C([C@]12O[C@@H]([C@@H]([C@@H]([C@H]([C@]32[H])O)C)OC(C4=CC=CN4)=O)[C@]3([H])C=C[C@]1([H])C[C@@H]5OC)=C\[C@H]([C@]([H])(OC5=O)[C@H](O)C)C

Molecular Formula

C28H37NO8

Molecular Weight

515.60

References & Citations

[1]Da Hye Kwon, et al. Nargenicin A1 attenuates lipopolysaccharide-induced inflammatory and oxidative response by blocking the NF-κB signaling pathway. EXCLI J. 2021 May 28;20:968-982.|[2]Dhakal D, et al. Characterization of Tailoring Steps of Nargenicin A1 Biosynthesis Reveals a Novel Analogue with Anticancer Activities. ACS Chem Biol. 2020 Jun 19;15 (6) :1370-1380.